Literature DB >> 25945020

Hepatitis B virus preS1 deletion is related to viral replication increase and disease progression.

Seoung-Ae Lee1, Ki-Jeong Kim1, Hong Kim1, Won-Hyuk Choi1, Yu-Sub Won1, Bum-Joon Kim1.   

Abstract

AIM: To investigate the clinical implications of hepatitis B virus (HBV) preS1 deletion.
METHODS: We developed a fluorescence resonance energy transfer-based real-time polymerase chain reaction (RT-PCR) that can detect four genotypes (wild type, 15-bp, 18-bp and 21-bp deletion). The PCR method was used in two cohorts of Korean chronic HBV subjects with genotype C infections. Cohort I included 292 chronic HBV subjects randomly selected from Cheju National University Hospital (Jeju, South Korea) or Seoul National University Hospital (Seoul, South Korea), and cohort II included 90 consecutive chronic HBV carriers recruited from Konkuk University Hospital (Seoul, South Korea); the cohort II patients did not have hepatocellular carcinoma or liver cirrhosis.
RESULTS: The method proposed in this study identified 341 of 382 samples (89.3%). Deletion variants were identified in 100 (29.3%) of the 341 detected samples. In both cohorts, the subjects with deletions had a significantly higher Hepatitis B virus e antigen (HBeAg)-positive seroprevalence [cohort I, wild (51.0%) vs deletion (75.0%), P < 0.001; cohort II, wild (69.2%) vs deletion (92.9%), P = 0.002] and higher HBV DNA levels [cohort I, wild (797.7 pg/mL) vs deletion (1678.9 pg/mL), P = 0.013; cohort II, wild (8.3 × 10(8) copies/mL) vs deletion (2.2 × 10(9) copies/mL), P = 0.049], compared to subjects with wild type HBV.
CONCLUSION: HBV genotype C preS1 deletion may affect disease progression in chronic HBV subjects through an extended duration of HBeAg seropositive status and increased HBV replications.

Entities:  

Keywords:  Genotype C; Hepatitis B virus; Hepatitis B virus e antigen; Hepatocellular carcinoma; PreS1 start codon deletion

Mesh:

Substances:

Year:  2015        PMID: 25945020      PMCID: PMC4408479          DOI: 10.3748/wjg.v21.i16.5039

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  Novel F141L pre-S2 mutation in hepatitis B virus increases the risk of hepatocellular carcinoma in patients with chronic genotype C infections.

Authors:  Ho-Suk Mun; Seoung-Ae Lee; Hong Kim; Eung-Soo Hwang; Yoon-Hoh Kook; Bum-Joon Kim
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

2.  A trans-activator function is generated by integration of hepatitis B virus preS/S sequences in human hepatocellular carcinoma DNA.

Authors:  W H Caselmann; M Meyer; A S Kekulé; U Lauer; P H Hofschneider; R Koshy
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

3.  Naturally occurring hepatitis B virus X deletions and insertions among Korean chronic patients.

Authors:  Seoung-Ae Lee; Ho-Suk Mun; Hong Kim; Hyung-Ki Lee; Buyng-Jun Kim; Eung-Soo Hwang; Yoon-Hoh Kook; Bum-Joon Kim
Journal:  J Med Virol       Date:  2011-01       Impact factor: 2.327

Review 4.  World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants.

Authors:  M L Funk; D M Rosenberg; A S F Lok
Journal:  J Viral Hepat       Date:  2002-01       Impact factor: 3.728

5.  Prevalent HBV point mutations and mutation combinations at BCP/preC region and their association with liver disease progression.

Authors:  Dake Zhang; Sufang Ma; Xin Zhang; Hanqing Zhao; Huiguo Ding; Changqing Zeng
Journal:  BMC Infect Dis       Date:  2010-09-16       Impact factor: 3.090

6.  Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.

Authors:  Chi-Jen Chu; Munira Hussain; Anna S F Lok
Journal:  Gastroenterology       Date:  2002-06       Impact factor: 22.682

7.  A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees.

Authors:  Y Itoh; E Takai; H Ohnuma; K Kitajima; F Tsuda; A Machida; S Mishiro; T Nakamura; Y Miyakawa; M Mayumi
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

8.  Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage.

Authors:  Yi-Hsuan Hsieh; Ih-Jen Su; Hui-Ching Wang; Wen-Wei Chang; Huan-Yao Lei; Ming-Derg Lai; Wen-Tsan Chang; Wenya Huang
Journal:  Carcinogenesis       Date:  2004-06-03       Impact factor: 4.944

9.  Hepatitis B virus X mutations occurring naturally associated with clinical severity of liver disease among Korean patients with chronic genotype C infection.

Authors:  Hyun-Ju Kim; Joo-Hee Park; Youngmee Jee; Seoung-Ae Lee; Hong Kim; Byung-Cheol Song; Soohyun Yang; Myunghee Lee; Jung-Hwan Yoon; Yoon Jun Kim; Hyo-Suk Lee; Eung-Soo Hwang; Yoon-Hoh Kook; Bum-Joon Kim
Journal:  J Med Virol       Date:  2008-08       Impact factor: 2.327

10.  Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma.

Authors:  Hwai-I Yang; Shiou-Hwei Yeh; Pei-Jer Chen; Uchenna H Iloeje; Chin-Lan Jen; Jun Su; Li-Yu Wang; Sheng-Nan Lu; San-Lin You; Ding-Shinn Chen; Yun-Fan Liaw; Chien-Jen Chen
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

View more
  9 in total

Review 1.  X region mutations of hepatitis B virus related to clinical severity.

Authors:  Hong Kim; Seoung-Ae Lee; Bum-Joon Kim
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

Review 2.  Precore/core region mutations of hepatitis B virus related to clinical severity.

Authors:  Hong Kim; Seoung-Ae Lee; Seung Yeon Do; Bum-Joon Kim
Journal:  World J Gastroenterol       Date:  2016-05-07       Impact factor: 5.742

Review 3.  Association of preS/S Mutations with Occult Hepatitis B Virus (HBV) Infection in South Korea: Transmission Potential of Distinct Occult HBV Variants.

Authors:  Hong Kim; Bum-Joon Kim
Journal:  Int J Mol Sci       Date:  2015-06-15       Impact factor: 5.923

4.  A Highly Sensitive Detection System based on Proximity-dependent Hybridization with Computer-aided Affinity Maturation of a scFv Antibody.

Authors:  Zhiheng Wang; Yan Li; Wenbin Liang; Junsong Zheng; Shuhui Li; Chuanmin Hu; An Chen
Journal:  Sci Rep       Date:  2018-03-01       Impact factor: 4.379

5.  Naturally occurring mutations in the reverse transcriptase region of hepatitis B virus polymerase from treatment-naïve Korean patients infected with genotype C2.

Authors:  Ji-Eun Kim; So-Young Lee; Hong Kim; Ki-Jeong Kim; Won-Hyeok Choe; Bum-Joon Kim
Journal:  World J Gastroenterol       Date:  2017-06-21       Impact factor: 5.742

6.  The N-Terminus Makes the Difference: Impact of Genotype-Specific Disparities in the N-Terminal Part of The Hepatitis B Virus Large Surface Protein on Morphogenesis of Viral and Subviral Particles.

Authors:  Bingfu Jiang; Xingjian Wen; Qingyan Wu; Daniela Bender; Gert Carra; Michael Basic; Alica Kubesch; Kai-Henrik Peiffer; Klaus Boller; Eberhard Hildt
Journal:  Cells       Date:  2020-08-13       Impact factor: 6.600

7.  The Genotype (A to H) Dependent N-terminal Sequence of HBV Large Surface Protein Affects Viral Replication, Secretion and Infectivity.

Authors:  Guomin Ou; Lingyuan He; Luwei Wang; Ji Song; Xinyuan Lai; Xing Tian; Lei Wang; Kai Zhang; Xuechao Zhang; Juan Deng; Hui Zhuang; Kuanhui Xiang; Tong Li
Journal:  Front Microbiol       Date:  2021-07-09       Impact factor: 5.640

8.  rt269I Type of Hepatitis B Virus (HBV) Polymerase versus rt269L Is More Prone to Mutations within HBV Genome in Chronic Patients Infected with Genotype C2: Evidence from Analysis of Full HBV Genotype C2 Genome.

Authors:  Hyein Jeong; Dong Hyun Kim; Yu-Min Choi; HyeLim Choi; Donghyun Kim; Bum-Joon Kim
Journal:  Microorganisms       Date:  2021-03-15

9.  A Hepatitis B Virus-Derived Peptide Can Inhibit Infection of Human Lung Cells with SARS-CoV-2 in a Type-1 Interferon-Dependent Manner.

Authors:  Yu-Min Choi; Hyein Jeong; Uni Park; Nam-Hyuk Cho; Bum-Joon Kim
Journal:  Viruses       Date:  2021-06-25       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.